Shanghai Lymphoma Clinical Cohort
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No interventions need to be specified for this study.
- Who it may be relevant to
- Registry conditions: Lymphoma, Cohort. Basic parameters: from 16 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.
Detailed description
Lymphoma is a common hematological malignancy. This study aims to prospectively collect clinical information on patients with lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best therapeutic strategies in the real-world population.
Interventions
- Other No interventions need to be specified for this study
No interventions need to be specified for this study
Primary outcome measures
- Progression Free Survival (PFS) [Time frame: Baseline up to data cut-off (up to approximately 1 year)]
Secondary outcome measures (1)
- Overall Survival (OS) [Time frame: Baseline up to data cut-off (up to approximately 1 year)]
Eligibility criteria
Inclusion criteria
- Age ≥ 16 years (including 16 years old).
- Patients newly diagnosed with non-Hodgkin lymphoma
- Patients who have received systematic clinical treatment.
- Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Exclusion criteria
- Patients who only receive supportive treatment.
- Patients who cannot obtain effective evaluation data of efficacy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07285174 · Shanghai Lymphoma Cohort